Fitch Upgrades Teva to Investment Grade Amid Pivot to Growth Execution

Rhea-AI Summary

Teva (NYSE:TEVA) reported that Fitch upgraded its corporate credit rating to investment grade BBB- with a stable outlook, up from BB+. Fitch also raised ratings on Teva’s senior unsecured debt and credit facilities to BBB-.

Fitch cites improved financial flexibility, a shift toward higher-margin innovative and biosimilar products, and expected growth driven by AUSTEDO, AJOVY, UZEDY and future launches such as olanzapine LAI, subject to regulatory approval. Teva remains rated BB+ (stable) by S&P and Ba1 (positive) by Moody’s.

Positive

• Fitch upgrades Teva corporate rating to investment grade BBB- with stable outlook
• Senior unsecured debt and credit facilities also raised to BBB- by Fitch
• Fitch highlights shift toward higher-margin innovative and biosimilar portfolio
• Fitch expects continued growth in innovative revenues from AUSTEDO, AJOVY and UZEDY
• Fitch cites efficiency programs supporting operating margin improvement and cash generation
• Fitch notes ongoing balance sheet strengthening and enhanced financial flexibility

Negative

• Teva remains below investment grade with S&P (BB+ stable) and Moody’s (Ba1 positive)
• Future growth contributions from olanzapine LAI depend on regulatory approval

News Market Reaction – TEVA

-0.76%

-0.76% Session close to close

In the May 18 session, TEVA declined 0.76%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement highlights Fitch’s upgrade of TEVA’s corporate rating to investment grade BBB- wit...

Analysis

This announcement highlights Fitch’s upgrade of TEVA’s corporate rating to investment grade BBB- with a stable outlook, reflecting progress in strengthening financial flexibility and shifting toward higher-margin innovative and biosimilar products. Recent history shows strong reactions to fundamental catalysts such as Q1 2026 results and portfolio expansions. Investors may focus on continued growth from AUSTEDO, AJOVY, UZEDY and upcoming launches, as well as ongoing margin and cash-flow trends.

Key Figures

Fitch corporate rating: BBB- Prior Fitch rating: BB+ Senior debt rating: BBB- +3 more

6 metrics

Fitch corporate rating BBB- Upgraded to investment grade with stable outlook

Prior Fitch rating BB+ Previous corporate credit rating before upgrade

Senior debt rating BBB- Fitch rating on senior unsecured debt and credit facilities

Fitch upgrades count 3 upgrades Third Fitch upgrade in less than two years

S&P rating BB+ S&P Global Ratings, stable outlook

Moody’s rating Ba1 Moody’s Investors Service, positive outlook

Historical Context

5 past events · Latest: May 04 (Neutral)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
May 04	Conference appearance	Neutral	+1.4%	Upcoming BofA healthcare conference presentation with webcast access details.
Apr 30	ESG/sustainability update	Positive	-0.9%	Healthy Future Report highlighting ESG progress and $7.5B sustainability-linked bond targets.
Apr 29	Product sales update	Positive	+11.9%	Strong UZEDY net sales growth and regulatory timelines for olanzapine LAI.
Apr 29	Earnings results	Positive	+11.9%	Q1 2026 results with innovative portfolio growth and maintained 2026 outlook.
Apr 29	Acquisition announcement	Positive	+11.9%	Planned Emalex acquisition adding NDA-ready ecopipam to neuroscience pipeline.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent fundamentally positive updates (earnings, product sales, acquisition) were often followed by strong gains around +11.89%, while softer or ESG-focused news saw more muted or slightly negative moves.

Recent Company History

Over the past few months, TEVA has reported several milestones, including strong Q1 2026 results with growth in innovative brands, robust UZEDY® sales, and the planned Emalex acquisition to bolster its neuroscience pipeline. These events each saw a +11.89% 24-hour price reaction. By contrast, the sustainability report and a conference appearance generated modest reactions (+1.44% and -0.88%). The current Fitch upgrade fits into a broader narrative of balance sheet strengthening and strategic execution.

Key Terms

investment grade, corporate credit rating, senior unsecured debt, credit facilities, +4 more

8 terms

investment grade financial

"Fitch Ratings Agency has raised the Company's corporate credit rating to Investment Grade BBB-"

A credit rating label assigned to bonds or borrowers that signals relatively low risk of default; think of it as a strong health check for a company's or government's ability to repay debt. It matters to investors because investment-grade status typically means lower interest costs for the borrower, greater eligibility for conservative funds and pension portfolios, and generally more stable returns compared with higher-risk, non-investment-grade debt.

View in glossary

corporate credit rating financial

"Fitch Ratings Agency has raised the Company's corporate credit rating to Investment Grade BBB-"

A corporate credit rating is a letter-grade assessment, issued by independent agencies, of a company’s ability to pay back its debts and meet interest obligations. Think of it like a personal credit score for a business: higher ratings mean lower risk and cheaper borrowing, while lower ratings signal greater risk and higher interest costs, which can affect bond returns, a company’s access to loans, and investor confidence in the stock.

senior unsecured debt financial

"Fitch has also upgraded its ratings on Teva's senior unsecured debt and credit facilities"

A senior unsecured debt is a loan or bond that a company must repay before other unsecured obligations but is not backed by specific assets as collateral. Think of it as being earlier in line for repayment, like a preferred ticket in a queue, but without a guarantee you’ll get property if the company fails; that priority reduces risk compared with junior debt and affects expected interest rates and recovery prospects for investors.

credit facilities financial

"Fitch has also upgraded its ratings on Teva's senior unsecured debt and credit facilities"

Credit facilities are arrangements with banks or lenders that let a company borrow money up to an agreed limit when it needs cash, similar to a business credit card or a home line of credit. They matter to investors because they show how a company manages short‑ and medium‑term financing needs, affect liquidity and debt levels, and can influence costs and risks if borrowing terms change or covenants are breached.

biosimilar medical

"transition toward a higher-margin innovative and biosimilar portfolio"

A biosimilar is a medicine created to be highly similar to an existing complex drug made from living cells, matching its safety and effectiveness while allowing for small, natural variations. For investors, biosimilars matter because they introduce lower-cost competition when patents end, which can cut prices, shift market share, and change revenue forecasts for companies selling the original drugs, much like a generic version does for simpler chemical medicines.

regulatory approval regulatory

"upcoming launches, including olanzapine LAI, subject to regulatory approval"

Regulatory approval is the official permission given by government agencies or authorities that allows a product, service, or business activity to be legally operated or sold. It is important to investors because receiving approval often indicates that a product has been reviewed for safety and compliance, which can influence its success and the company’s prospects in the market. Without this approval, launching or selling certain products may be restricted or prohibited.

operating margin financial

"portfolio shift to support its operating margin improvement and continued strong cash generation"

Operating margin shows how much profit a company makes from its core business activities after paying for costs like wages and materials. It’s useful because it tells you how efficiently a company is running—higher margins mean it keeps more money from each dollar of sales, which can indicate better management or stronger products.

View in glossary

cash generation financial

"support its operating margin improvement and continued strong cash generation"

Cash generation is a company's ability to convert its business activity into actual cash flowing into the bank rather than accounting profits. It matters to investors because cash funds day‑to‑day operations, growth projects, dividends and debt repayment; strong cash generation is like a household with steady paychecks, giving more flexibility and less risk when times get tight.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

TEL AVIV, Israel, May 18, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Fitch Ratings Agency (“Fitch”) has raised the Company's corporate credit rating to Investment Grade BBB-, with a stable outlook, from BB+.

“This strong endorsement, our third upgrade from Fitch in less than two years, underscores Teva’s transformation journey and execution of its Pivot to Growth strategy, as well as shows confidence in our increasing financial flexibility” said Eli Kalif, Teva’s Chief Financial Officer.

Fitch has also upgraded its ratings on Teva's senior unsecured debt and credit facilities to BBB- from BB+.

Fitch’s report highlights Teva’s sustained progress in strengthening financial flexibility and advancing its transition toward a higher-margin innovative and biosimilar portfolio. Fitch expects continued growth in innovative revenues, led by AUSTEDO® and AJOVY®; as well as contributions from recently launched products such as UZEDY® and upcoming launches, including olanzapine LAI, subject to regulatory approval. Fitch also expects Teva’s efficiency programs and portfolio shift to support its operating margin improvement and continued strong cash generation. Fitch further noted Teva’s ongoing balance sheet strengthening, supported by sustained cash flow generation, enhancing financial flexibility.

Teva is currently rated BB+ with stable outlook by S&P Global Ratings and Ba1 with positive outlook by Moody’s Investors Service.

About Teva 
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is transforming into a leading innovative biopharmaceutical company, enabled by a world-class generics business. For over 120 years, Teva’s commitment to bettering health has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars and pharmacy brands worldwide, Teva is dedicated to addressing patients’ needs, now and in the future. At Teva, We Are All In For Better Health. To learn more about how, visit www.tevapharm.com. 

Cautionary Note Regarding Forward-Looking Statements  
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding our financial guidance, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. These forward-looking statements include statements concerning our plans, strategies, objectives, future performance and financial and operating targets, and any other information that is not historical information. You can identify these forward-looking statements by the use of words such as “should,” “expect,” “anticipate,” “estimate,” “target,” “may,” “project,” “guidance,” “intend,” “plan,” “believe” and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance. Important factors that could cause or contribute to such differences include risks relating to: our ability to continue and improve our financial ratings; our ability to develop and commercialize additional pharmaceutical products such as olanzapine LAI; competition for our innovative medicines; our ability to achieve expected results from investments in our product pipeline; our ability to successfully execute our Pivot to Growth strategy, including to expand our innovative and biosimilar medicines pipeline and profitably commercialize the innovative medicines and biosimilar portfolio, whether organically or through business development, to sustain and focus our portfolio of generic medicines, and to execute on our organizational transformation and to achieve expected cost savings; our significant indebtedness; compliance, regulatory and litigation matters; other financial and economic risks; and other factors discussed in this Press Release, in our Quarterly Report on Form 10-Q for the first quarter of 2026 and in our Annual Report on Form 10-K for the year ended December 31, 2025, including in the sections captioned “Risk Factors” and “Forward-looking Statements.” Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements. 

Teva Media Inquiries	TevaCommunicationsNorthAmerica@tevapharm.com
Teva Investor Relations Inquiries	TevaIR@Tevapharm.com

FAQ

What rating upgrade did Fitch announce for Teva (NYSE:TEVA) on May 18, 2026?

Fitch upgraded Teva’s corporate credit rating to investment grade BBB- with a stable outlook. According to Teva, Fitch also raised ratings on its senior unsecured debt and credit facilities to BBB-, reflecting stronger financial flexibility and progress executing the Pivot to Growth strategy.

Why did Fitch upgrade Teva (TEVA) to investment grade BBB-?

Fitch upgraded Teva based on strengthened financial flexibility and a shift toward higher-margin innovative and biosimilar products. According to Teva, Fitch highlighted efficiency programs, expected operating margin improvement, strong cash generation, and growing innovative revenues led by AUSTEDO, AJOVY, UZEDY and upcoming launches.

Which Teva (TEVA) products does Fitch expect to drive innovative revenue growth?

Fitch expects innovative revenue growth led by AUSTEDO and AJOVY, with contributions from UZEDY. According to Teva, Fitch also anticipates additional impact from upcoming launches including olanzapine LAI, which remains subject to regulatory approval before commercialization can occur.

How do S&P and Moody’s currently rate Teva (TEVA) after the Fitch upgrade?

Teva remains rated below investment grade by S&P and Moody’s despite Fitch’s BBB- upgrade. According to Teva, S&P rates the company BB+ with a stable outlook, while Moody’s assigns a Ba1 rating with a positive outlook, indicating potential for future improvement.

What does the Fitch investment grade rating mean for Teva (TEVA) investors?

The Fitch BBB- investment grade rating signals improved perceived credit quality and financial flexibility. According to Teva, Fitch cited stronger cash generation, balance sheet strengthening, and a higher-margin portfolio, factors that may influence financing costs and market perception of Teva’s long-term credit profile.

How does Teva’s Pivot to Growth strategy relate to Fitch’s rating decision on TEVA?

Fitch’s upgrade reflects perceived progress in Teva’s Pivot to Growth execution. According to Teva, Fitch pointed to the transition toward innovative and biosimilar products, efficiency programs, and expected margin improvement, all central elements of the company’s growth-focused strategic shift.